Involvement of K(ATP)/PI (3)K/AKT/Bcl-2 pathway in hydrogen sulfide-induced neuroprotection against the toxicity of 1-methy-4-phenylpyridinium ion

J Mol Neurosci. 2012 Feb;46(2):442-9. doi: 10.1007/s12031-011-9608-1. Epub 2011 Jul 29.

Abstract

We previously reported that hydrogen sulfide (H(2)S) produces protection in PC12 cells during 1-methy-4-phenylpyridinium ion (MPP(+)) challenge. The present study aims to clarify the mechanisms underlying the neuroprotective effects of H(2)S. We showed that both glybenclamide, an ATP-sensitive potassium (K(ATP)) channel blocker, and LY294002, a specific PI(3)K-AKT pathway inhibitor, reversed the neuroprotective effect of NaHS (a H(2)S donor) against MPP(+)-induced cytotoxicity to PC12 cells and that NaHS up-regulated the activity of AKT in PC12 cells, which was abolished by blockade of K(ATP) channels with glybenclamide. In addition, NaHS up-regulated the expression of Bcl-2 and blocked MPP(+)-induced down-regulation of Bcl-2, and this augmentation of Bcl-2 expression was prevented by both glybenclamide and LY294002. These data provided the evidence that the neuroprotective action of H(2)S against MPP(+) toxicity to PC12 cells is via the K(ATP)/PI(3)K/AKT/Bcl-2 pathway. We also demonstrated that NaHS attenuated the inhibitory effect of MPP(+) ERK1/2 activation in PC12 cells, whereas U0126, a specific MEK inhibitor, did not reverse the neuroprotective effect of NaHS, which indicated that attenuating MPP(+)-triggered down-regulation of ERK1/2 activation is involved in the protection of H(2)S against MPP(+) neurotoxicity, but ERK1/2 is not an essential effector mediating the neuroprotective effect of H(2)S. In conclusion, the present observations identify a crucial role of the K(ATP)/PI(3)K/AKT/Bcl-2 pathway in H(2)S-exerted neuroprotection against the toxicity of MPP(+). Findings from the present study will help shed light on the mechanisms of H(2)S-elicited neuroprotective effects on MPP(+) toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenylpyridinium / toxicity*
  • Animals
  • Butadienes / pharmacology
  • Gene Expression Regulation / drug effects
  • Genes, bcl-2 / drug effects
  • Glyburide / pharmacology
  • Hydrogen Sulfide / pharmacology*
  • In Vitro Techniques
  • KATP Channels / physiology*
  • MAP Kinase Signaling System / drug effects
  • MPTP Poisoning / prevention & control
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / biosynthesis
  • Nerve Tissue Proteins / physiology*
  • Neurons / drug effects*
  • Neurons / metabolism
  • Neuroprotective Agents / pharmacology*
  • Neurotoxins / toxicity*
  • Nitriles / pharmacology
  • PC12 Cells / drug effects
  • PC12 Cells / metabolism
  • Phosphatidylinositol 3-Kinases / physiology*
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Potassium Channel Blockers / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Processing, Post-Translational / drug effects
  • Proto-Oncogene Proteins c-akt / antagonists & inhibitors
  • Proto-Oncogene Proteins c-akt / physiology*
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis
  • Proto-Oncogene Proteins c-bcl-2 / physiology*
  • Rats
  • Signal Transduction / drug effects*

Substances

  • Butadienes
  • KATP Channels
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Neurotoxins
  • Nitriles
  • Phosphoinositide-3 Kinase Inhibitors
  • Potassium Channel Blockers
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-bcl-2
  • U 0126
  • Akt1 protein, rat
  • Proto-Oncogene Proteins c-akt
  • 1-Methyl-4-phenylpyridinium
  • Glyburide
  • Hydrogen Sulfide